Given that UHRF1 is required for SIRT6-deficient BLCA in driving tumor growth, we therefore questioned whether the UHRF1 specific inhibitor, NSC232003, could effectively suppress BLCA. Here, UHRF1 is linked to bladder transitional cell carcinoma.